Healthpeak Properties, Inc.
DOCReal Estate Reit Healthcare Facilities
Healthpeak Properties, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.8 billion, up 4.52% from fiscal 2024.
- Revenue
- +16.3%
- EPS
- n/m
- Free cash flow
- n/m
- Total debt
- +2.75%
Quarter to September 2026, against a year earlier
After hours trading: 19.44, up 0.99%, last trade 7:39pm Eastern.
Follow DOC
Alert me
Healthpeak Properties, Inc. (DOC) valuation and DCF model
At $19.25 the price implies FFO a share growing −2.7% a year for ten years.
FFO a share grew −11.5% a year over the last ten years, 11.0% over the last five. The price asks for 8.8 points a year more than its ten-year rate. The industry’s median company is priced for 4.6%.
In December 2017 the price assumed 25.7% a year; Healthpeak Properties, Inc. went on to grow FFO a share 17.9% a year to FY2025.
FFO a share is worked out from Healthpeak Properties, Inc.’s 10-Ks and 10-Qs: net income, plus the depreciation of its property and impairments, less gains on property sales.
- The price needs
- −2.7% a year for ten years
- $19.25
- today’s price
- Its base case
- −10.0% a year for five years, then −6.0%
- $12.69
- 34.1% below today’s price
Base case on its own ten-year record Healthpeak Properties, Inc.’s own growth, carried forward
Its assumptions
Powerpack lets you start from a scenario and type over any of them.
How we got there$7.51 10 years of FFO+$5.19 terminal value=$12.69 per share
Valuation against its own history
| Multiple | Current | 5Y avg | 10Y avg | vs 10Y avg | Industry median | vs industry | 10Y range |
|---|---|---|---|---|---|---|---|
| P/E | 35.65× | 63.50× | 78.16× | 54% below | 24.33× | 47% above | |
| P/FCF | — | 51.19× | 35.86× | — | 21.43× | — | |
| P/B | 1.23× | 1.52× | 1.94× | 36% below | 1.60× | 23% below | |
| EV/EBITDA | 14.75× | 16.65× | 20.40× | 28% below | 14.75× | 0% above | |
| EV/Sales | 7.19× | 8.11× | 10.14× | 29% below | 7.80× | 8% below | |
| P/FFO | 10.71× | 11.06× | 26.05× | 59% below | — | — |
DOC trades at 35.65× P/E, against a 10-year average of 78.16× (range 12.52×–344.70×). That is cheaper than 67% of the last 9 year-end readings; re-rating to the average implies $42.20 per share.